Ioannis Ntanasis-Stathopoulos, MD, PhD, National and Kapodistrian University of Athens, Athens, Greece, discusses the value of using circulating tumor cells (CTCs) as a prognostic tool in patients with newly diagnosed multiple myeloma (NDMM). This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.